

Guopei Zheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4627913/publications.pdf>

Version: 2024-02-01

33
papers

1,265
citations

257101

24
h-index

433756

31
g-index

33
all docs

33
docs citations

33
times ranked

1901
citing authors

#	ARTICLE	IF	CITATIONS
1	LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer. <i>Oncogene</i> , 2018, 37, 6166-6179.	2.6	101
2	miR-218 suppresses gastric cancer cell cycle progression through the CDK6/Cyclin D1/E2F1 axis in a feedback loop. <i>Cancer Letters</i> , 2017, 403, 175-185.	3.2	90
3	Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis. <i>Cell Death and Differentiation</i> , 2020, 27, 966-983.	5.0	85
4	Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 14913-14925.	0.8	76
5	The lncRNA MIR4435-2HG promotes lung cancer progression by activating β -catenin signalling. <i>Journal of Molecular Medicine</i> , 2018, 96, 753-764.	1.7	72
6	lncRNA <i>i>THAP9-AS1</i> Promotes Pancreatic Ductal Adenocarcinoma Growth and Leads to a Poor Clinical Outcome via Sponging miR-484 and Interacting with YAP. <i>Clinical Cancer Research</i>, 2020, 26, 1736-1748.</i>	3.2	70
7	Diallyl Disulfide Suppresses SRC/Ras/ERK Signaling-Mediated Proliferation and Metastasis in Human Breast Cancer by Up-Regulating miR-34a. <i>PLoS ONE</i> , 2014, 9, e112720.	1.1	67
8	KLF5 regulated lncRNA RP1 promotes the growth and metastasis of breast cancer via repressing p27kip1 translation. <i>Cell Death and Disease</i> , 2019, 10, 373.	2.7	61
9	MicroRNA-493 Suppresses Tumor Growth, Invasion and Metastasis of Lung Cancer by Regulating E2F1. <i>PLoS ONE</i> , 2014, 9, e102602.	1.1	52
10	Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer. <i>Nature Communications</i> , 2021, 12, 2699.	5.8	46
11	miR-22/KAT6B axis is a chemotherapeutic determiner via regulation of PI3k-Akt-NF- κ B pathway in tongue squamous cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 164.	3.5	41
12	A Bmi1-miRNAs Cross-Talk Modulates Chemotherapy Response to 5-Fluorouracil in Breast Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e73268.	1.1	41
13	ZEB1 transcriptionally regulated carbonic anhydrase 9 mediates the chemoresistance of tongue cancer via maintaining intracellular pH. <i>Molecular Cancer</i> , 2015, 14, 84.	7.9	35
14	FOXO3a-driven miRNA signatures suppresses VEGF-A/NRP1 signaling and breast cancer metastasis. <i>Oncogene</i> , 2021, 40, 777-790.	2.6	35
15	Epigenetic silencing of miR-493 increases the resistance to cisplatin in lung cancer by targeting tongue cancer resistance-related protein 1 (TCRP1). <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 114.	3.5	34
16	lncRNA LINC01057 promotes mesenchymal differentiation by activating NF- κ B signaling in glioblastoma. <i>Cancer Letters</i> , 2021, 498, 152-164.	3.2	34
17	lncRNA SNORD3A specifically sensitizes breast cancer cells to 5-FU by sponging miR-185-5p to enhance UMP5 expression. <i>Cell Death and Disease</i> , 2020, 11, 329.	2.7	33
18	Microarray-Assisted Pathway Analysis Identifies MT1X & NF- κ B as Mediators of TCRP1-Associated Resistance to Cisplatin in Oral Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2012, 7, e51413.	1.1	32

#	ARTICLE	IF	CITATIONS
19	SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell. <i>Cellular Signalling</i> , 2014, 26, 2710-2720.	1.7	31
20	Identification of proteins responsible for the multiple drug resistance in 5-fluorouracil-induced breast cancer cell using proteomics analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1477-1488.	1.2	28
21	HSP27-Mediated Extracellular and Intracellular Signaling Pathways Synergistically Confer Chemoresistance in Squamous Cell Carcinoma of Tongue. <i>Clinical Cancer Research</i> , 2018, 24, 1163-1175.	3.2	28
22	Identification of carbonic anhydrase-9 as a contributor to pingyangmycin-induced drug resistance in human tongue cancer cells. <i>FEBS Journal</i> , 2010, 277, 4506-4518.	2.2	27
23	TCRP1 promotes radioresistance of oral squamous cell carcinoma cells via Akt signal pathway. <i>Molecular and Cellular Biochemistry</i> , 2011, 357, 107-113.	1.4	26
24	Cloning and functional characterization of TCRP1, a novel gene mediating resistance to cisplatin in an oral squamous cell carcinoma cell line. <i>FEBS Letters</i> , 2011, 585, 881-887.	1.3	25
25	Purification and biochemical characterization of a novel protein tongue cancer chemotherapy resistance-associated protein1 (TCRP1). <i>Protein Expression and Purification</i> , 2012, 82, 360-367.	0.6	20
26	TCRP1 regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF7 breast cancer cells via Akt inactivation. <i>FEBS Letters</i> , 2012, 586, 163-168.	1.3	19
27	TCRP1 transcriptionally regulated by c-Myc confers cancer chemoresistance in tongue and lung cancer. <i>Scientific Reports</i> , 2017, 7, 3744.	1.6	18
28	Activation of FOXO3a reverses 5-Fluorouracil resistance in human breast cancer cells. <i>Experimental and Molecular Pathology</i> , 2018, 105, 57-62.	0.9	13
29	TCRP1 contributes to cisplatin resistance by preventing Pol β degradation in lung cancer cells. <i>Molecular and Cellular Biochemistry</i> , 2015, 398, 175-183.	1.4	12
30	TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells. <i>Oncology Letters</i> , 2017, 13, 1398-1405.	0.8	11
31	TCRP1 activated by mutant p53 promotes NSCLC proliferation via inhibiting FOXO3a. <i>Oncogenesis</i> , 2022, 11, 19.	2.1	2
32	Simultaneous amplification of exons 18 to 21 of the <i>EGFR</i> gene using 5' tailed primers and a two-stage protocol. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2018, 37, 1-19.	0.4	0
33	TAS-102 has a tumoricidal activity in multiple myeloma. <i>American Journal of Cancer Research</i> , 2020, 10, 3752-3764.	1.4	0